Neurofilament Antibody Sampler Kit #9781
Product Information
Kit Usage Information
Protocols
Product Description
Specificity / Sensitivity
Neurofilament-L (DA2) Mouse mAb and Neurofilament-L (C28E10) Rabbit mAb detect endogenous levels of total Neurofilament-L protein. Neurofilament-M (RMO 14.9) Mouse mAb detects endogenous levels of total Neurofilament-M protein. Neurofilament-H (RMdO 20) Mouse mAb detects endogenous levels of total Neurofilament-H protein. Neurofilament-H (RMdO 20) Mouse mAb has been reported to detect NFM and NFH in human samples but only NFH in mouse, rat or bovine samples (Lee, V.M. et al., 1988).
Source / Purification
Monoclonal antibodies are produced by immunizing animals with purified and enzymatically dephosphorylated pig neurofilament, light chain (Neurofilament-L (DA2)), a synthetic peptide surrounding Glu450 of human Neurofilament-L (Neurofilament-L (C28E10)), rat neurofilament medium chain
(Neurofilament-M (RMO 14.9)), or rat neurofilament (Neurofilament-H (RMdO 20)).
#2836 Monoclonal antibody is produced by immunizing animals with rat neurofilament.
#2835 Monoclonal antibody is produced by immunizing animals with purified and enzymatically dephosphorylated pig neurofilament, light chain.
#2837 Monoclonal antibody is produced by immunizing animals with a synthetic peptide surrounding Glu450 of human Neurofilament-L.
#2838 Monoclonal antibody is produced by immunizing animals with rat neurofilament, medium chain.
Background
The cytoskeleton consists of three types of cytosolic fibers: actin microfilaments, intermediate filaments, and microtubules. Neurofilaments are the major intermediate filaments found in neurons and consist of light (NFL), medium (NFM), and heavy (NFH) subunits (1). Similar in structure to other intermediate filament proteins, neurofilaments have a globular amino-terminal head, a central α-helical rod domain, and a carboxy-terminal tail. A heterotetrameric unit (NFL-NFM and NFL-NFH) forms a protofilament, with eight protofilaments comprising the typical 10 nm intermediate filament (2). While neurofilaments are critical for radial axon growth and determine axon caliber, microtubules are involved in axon elongation. PKA phosphorylates the head domain of NFL and NFM to inhibit neurofilament assembly (3,4). Research studies have shown neurofilament accumulations in many human neurological disorders, including Parkinson's disease (in Lewy bodies along with α-synuclein), Alzheimer's disease, Charcot-Marie-Tooth disease, and Amyotrophic Lateral Sclerosis (ALS) (1).
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.